News coverage about Sarepta Therapeutics (NASDAQ:SRPT) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Sarepta Therapeutics earned a coverage optimism score of 0.16 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 46.0532327820267 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the media headlines that may have impacted Accern Sentiment’s analysis:
- Stocks Trend Prediction: Sarepta Therapeutics, Inc. (SRPT), Ross Stores, Inc. (ROST) – Market Movers (financialqz.com)
- Sarepta: Rosy Prospects Continue, Buying On Dips – Seeking Alpha (seekingalpha.com)
- Stocks Trend Prediction: Intrexon Corporation (XON), Sarepta Therapeutics, Inc. (SRPT) – Market Movers (financialqz.com)
- Will These Stocks Remain Hot? Sarepta Therapeutics, Inc. (SRPT), Ocean Power Technologies, Inc. (OPTT) – Market Movers (financialqz.com)
- You Can’t Reason With a Steamroller (finance.yahoo.com)
Several analysts recently weighed in on the stock. BidaskClub upgraded shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday. Janney Montgomery Scott initiated coverage on shares of Sarepta Therapeutics in a report on Wednesday, January 3rd. They set a “buy” rating and a $75.00 target price on the stock. HC Wainwright set a $75.00 target price on shares of Sarepta Therapeutics and gave the company a “buy” rating in a report on Wednesday, January 3rd. Zacks Investment Research cut shares of Sarepta Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, January 5th. Finally, Oppenheimer restated a “buy” rating and set a $76.00 target price on shares of Sarepta Therapeutics in a report on Wednesday, December 27th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and eighteen have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $63.88.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.86) by $0.66. The company had revenue of $45.95 million during the quarter, compared to the consensus estimate of $41.29 million. Sarepta Therapeutics had a negative return on equity of 51.72% and a negative net margin of 112.08%. During the same period in the previous year, the company posted ($0.95) EPS. research analysts predict that Sarepta Therapeutics will post -3.07 EPS for the current year.
In other news, SVP Shamim Ruff sold 10,000 shares of the stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $55.00, for a total transaction of $550,000.00. Following the completion of the transaction, the senior vice president now directly owns 37,045 shares in the company, valued at approximately $2,037,475. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Douglas S. Ingram purchased 38,138 shares of the firm’s stock in a transaction that occurred on Wednesday, November 8th. The shares were bought at an average price of $52.44 per share, for a total transaction of $1,999,956.72. Following the acquisition, the chief executive officer now directly owns 420,196 shares in the company, valued at approximately $22,035,078.24. The disclosure for this purchase can be found here. Insiders own 9.60% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This story was first published by BBNS and is the sole property of of BBNS. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://baseballnewssource.com/markets/sarepta-therapeutics-srpt-receiving-somewhat-favorable-media-coverage-study-finds/1821689.html.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.